The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Coding Corner Answer: September

Coding Corner Answer: September

September 1, 2014 • By Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Answer

CPT: 96413, 96415 x1, J1745 x 19 J1745-JW* x 1

You Might Also Like
  • Coding Corner Answer: March
  • Coding Corner Answer: July Coding Challenge
  • Rheumatology Coding Corner Answer: Billing Infusion Procedure with JW Modifier
Explore This Issue
September 2014
Also By This Author
  • Paget’s Disease of Bone

Diagnosis: ICD-9 714.0 and ICD-10 M05.09

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Rationale: The 2014 AMA Current Procedural Terminology manual states, “Chemotherapy administration codes 96401-96549 apply to parenteral administration of non-radionuclide anti-neoplastic drugs; and also to anti-neoplastic agents provided for treatment of non-cancer diagnoses (e.g., cyclophosphamide for auto-immune conditions) or to substances such as certain monoclonal antibody agents.”

The infliximab infusion is a highly complex biologic code, which should be coded to CPT 96413 for the first hour of infusion, and CPT 96415 is used to code each additional hour of the infusion up to eight hours. Because the patient’s infliximab was infused over two hours and 10 minutes, it is coded with both 96413 and 96415×1. Note that in order for an additional hour to be billed, the infusion would have to be at least 31 minutes into the next hour. The time does not start for the infusion until the actual medication is started, not when the IV port is inserted.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

J1745 is the drug HCPCS code for infliximab 10 mg, of which the patient received 200 mg. The correct way to code for the drug is J1745 x 20 (20 x 10 = 200 mg). According to the CMS infliximab medical policy for the diagnosis of RA, the dosage allowed is 3 mg/kg IV. If the patient currently weighs 135 lbs., that means she would be allowed 61.24 kg x 3, which equals 183.72 mg of infliximab that should be used. Because infliximab comes in 10 mg vials, the dosage would be rounded up to 19 vials. The other 10 mg would have to be documented as drug wastage and coded with a modifier JW to indicate drug wastage.

*Currently, Medicare does not require the use of the JW modifier, but still requires documentation in the medical record of any drug wastage. Many private carriers do require the use of the JW modifier with the wasted drug listed on a separate line, and the medical record must clearly document why and how much drug was wasted.

Filed Under: Billing/Coding, Biologics & Biosimilars, Drug Updates, From the College, Practice Management Tagged With: AC&R, American College of Rheumatology, Billing, Biologics, Coding, drug, ICD-10, infliximab, Practice Management, rheumatologyIssue: September 2014

You Might Also Like:
  • Coding Corner Answer: March
  • Coding Corner Answer: July Coding Challenge
  • Rheumatology Coding Corner Answer: Billing Infusion Procedure with JW Modifier
  • Rheumatology Coding Corner Answer: Physical Examination with Infliximab Infusion

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)